Please ensure Javascript is enabled for purposes of website accessibility

The Hidden Winner of the FDA’s Anti-Generic Decision

By Dave Williamson - Apr 17, 2013 at 7:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

David Williamson discusses Acura's big 33% pop post-FDA decision.

In this video, Motley Fool health-care analyst David Williamson discusses the hidden winner of today's big FDA decision not to approve generic OxyContin despite a patent running out this week.

Big Pharma Pfizer sells an abuse-resistant, instant-acting version that will now avoid generic competition, but the hidden winner is the company whose technology makes the drug possible -- Acura Pharmaceuticals. This small cap popped more than 50% intraday, before settling with a 33% gain. Watch and find out what this means for investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$53.41 (1.00%) $0.53
Acura Pharmaceuticals, Inc. Stock Quote
Acura Pharmaceuticals, Inc.
$0.35 (-34.34%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.